Search
071217_COPD_infographic.pdf
BI_asthma_infographic.pdf
live_well_with_gpp_infographic.pdf
PPP-infographic.pdf
GPP-infographic.pdf
il-36-infographic.pdf
OFEV® (nintedanib) Overview Factsheet
Jardiance® (empagliflozin) Overview Factsheet | PDF
CardioMetabolic_infographic_Update_2021.pdf
Colorectal_Cancer_Infographic.pdf
786210066 - SSc_INFOGRAPHIC_CC06.pdf
Interview with Norbert Kraut: How cancer drives us forward
Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies
Candice is moving to Germany
Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.
Online application
Online application | FAQ
Internal application
Internal applications | FAQ
Emerging Talent
At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
Christina Schmitt
Christina Schmitt loves that she can be creative every day as a biopharma management trainee at Boehringer Ingelheim.
Dr. Hsing-Jung Chen-Engerer
Dr. Hsing-Jung Chen-Engerer of Research & Development speaks about his fulfilling career with Boehringer Ingelheim.
Irene Anindita
Irene Anindita is a Multichannel Manager for Cardiovascular and Metabolism Team in Amsterdam, the Netherlands, and really loves the vibe.
Alex Breiner
Alexandra Breiner, a Senior Communications Manager in Corporate Affairs, highlights her career and the many development programmes at Boehringer Ingelheim.
Ann-Kathrin Koller
Career choices, culture, the future and more with Ann-Kathrin Koller.
Stefanie Bock Kreilinger
Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
Nadine Becker
Nadine Becker, speaks about her role in the Master Data Management and her 20 year career in Boehringer Ingelheim.
Update on LUME-Meso Clinical Trial
Click here to read an update on the LUME-Meso clinical trial, comparing nintedanib with other treatment options for malignant pleural mesothelioma.